Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Cent 2(1):1–9. https://doi.org/10.1016/j.jncc.2022.02.002

Article  PubMed  PubMed Central  Google Scholar 

Xiang Z, Ye Z, Ma J, Lin Y, Zhou Y (2022) Temporal trends and projections of bladder cancer burden in China from 1990 to 2030: findings from the global burden of disease study. Clin Epidemiol. https://doi.org/10.2147/clep.s387289

Article  PubMed  PubMed Central  Google Scholar 

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG (2020) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. https://doi.org/10.1016/j.eururo.2020.03.055

Article  PubMed  PubMed Central  Google Scholar 

Nataliya M, Terence WF, Christopher JH, Thomas WF, Mehmet Asim B, Arjun Vasant B, Elizabeth H, Sandy S, Jonathan ER, Daniel Peter P, Earle Frederick B, Jaime RM, Scott TT, Anne-Sophie C, Joyce Leta S, Marya FC, Matthew IM (2020) Study EV-103: new randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. J Clin Oncol. https://doi.org/10.1200/jco.2020.38.15_suppl.tps5092

Article  Google Scholar 

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO null n (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. New Engl J Med. https://doi.org/10.1056/nejmoa1817323

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P (2021) TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. https://doi.org/10.1200/jco.20.03489

Article  PubMed  PubMed Central  Google Scholar 

Chen M, Yao K, Cao M, Liu H, Xue C, Qin T, Meng L, Zheng Z, Qin Z, Zhou F, Liu Z, Shi Y, An X (2023) HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-023-03419-1

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)00561-4

Article  PubMed  Google Scholar 

Mancini M, Righetto M, Noessner E (2021) Checkpoint inhibition in bladder cancer: clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach. Cancers. https://doi.org/10.3390/cancers13236016

Article  PubMed  PubMed Central  Google Scholar 

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee J-L, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J, null n (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(20)30541-6

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SYS, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, null n (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(21)00152-2

Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou T-Y, Chung J-H, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2018.05.013

Article  PubMed  PubMed Central  Google Scholar 

Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen S-J, Baden J, Barrett JC, Beer P, Butler M, Cheng J-H, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li M-C, Macconaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang X, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J (2021) Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. https://doi.org/10.1016/j.annonc.2021.09.016

Article  PubMed  Google Scholar 

Li R, Han D, Shi J, Han Y, Tan P, Zhang R, Li J (2020) Choosing tumor mutational burden wisely for immunotherapy: a hard road to explore. Biochimica et Biophysica Acta (BBA) - Rev Cancer. https://doi.org/10.1016/j.bbcan.2020.188420

Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD (2019) Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2019.06.025

Article  PubMed  PubMed Central  Google Scholar 

Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG (2020) Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. https://doi.org/10.1016/j.cell.2020.07.017

Article  PubMed  PubMed Central  Google Scholar 

Sun D, Guan X, Moran AE, Wu L-Y, Qian DZ, Schedin P, Dai M-S, Danilov AV, Alumkal JJ, Adey AC, Spellman PT, Xia Z (2021) Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. https://doi.org/10.1038/s41587-021-01091-3

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, Hu J, Chen K (2020) Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. https://doi.org/10.1038/s41467-020-18916-5

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Sebra RP, Sfakianos JP, Allette K, Wang W, Yoo S, Bhardwaj N, Schadt EE, Yao X, Galsky MD, Zhu J (2020) A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. Genome Med 12(1):24. https://doi.org/10.1186/s13073-020-0720-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548. https://doi.org/10.1038/nature25501

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY (2021) Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 125(9):1251–1260. https://doi.org/10.1038/s41416-021-01488-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O’Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale DZ, Wobker SE, Hoadley KA, Kim WY, Milowsky MI (2022) Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun 13(1):6658. https://doi.org/10.1038/s41467-022-33980-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400-416.e411. https://doi.org/10.1016/j.cell.2018.02.052

Article  CAS  PubMed  PubMed Central  Google Scholar 

(2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-322. https://doi.org/10.1038/nature12965

Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9:3. https://doi.org/10.1186/1476-4598-9-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sjödahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, Johansson I, Kollberg P, Lindh C, Lövgren K, Marzouka NA, Olsson H, Höglund M, Ullén A, Liedberg F (2022) Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol 81(5):523–532. https://doi.org/10.1016/j.eururo.2021.10.035

Article  CAS  PubMed  Google Scholar 

Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18(5):1323–1333. https://doi.org/10.1158/1078-0432.Ccr-11-2271

Article  CAS